|
Age (at time of recurrence), median (range)
|
74 (57–84)
|
70 (49–85)
|
|
Sex
| | |
Male
Female
|
8 (57%)
6 (43%)
|
14 (58%)
10 (42%)
|
|
ECOG (at time of recurrence)
| | |
0
1
2
3
|
0 (0%)
13 (93%)
1 (7%)
0 (0%)
|
4 (17%)
15 (63%)
5 (21%)
0 (0%)
|
|
Tumor stage (at initial presentation)
| | |
T1
T2
|
12 (86%)
2 (14%)
|
22 (92%)
2 (8%)
|
|
Histology
| | |
Adenocarcinoma
Squamous
Other
|
10 (71%)
4 (29%)
0 (0%)
|
16 (67%)
7 (29%)
1 (4%)
|
|
EBUS performed initially
|
10 (71%)
|
20 (83%)
|
|
Recurrence confirmed
| | |
Biopsy
PET-CT
CT
|
7 (50%)
4 (29%)
3 (21%)
|
24 (100%)
0 (0%)
0 (0%)
|
|
Median time to recurrence from 1st SABR, mo (range)
|
20 (3–60)
|
16 (5–54)
|
|
Median follow-up time from the time of re-RT, mo (IQR)
|
36 (19–45)
|
18 (8–38)
|
|
OS after re-RT (95% CI)
| | |
1-year rate, %
3-year rate, %
5-year rate, %
|
86% (54–96%)
63% (32–83%)
54% (24–76%)
|
70% (47–84%)
35% (17–54%)
16% (3–36%)
|